{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:33:02Z","timestamp":1772119982667,"version":"3.50.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82122033"],"award-info":[{"award-number":["82122033"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Major Research Plan of National Natural Science Foundation of China","award":["92259304"],"award-info":[{"award-number":["92259304"]}]},{"name":"Innovation Chain of Key Industries in Shaanxi Province","award":["S2024-YF-ZDCXL-ZDLSF-0064"],"award-info":[{"award-number":["S2024-YF-ZDCXL-ZDLSF-0064"]}]},{"name":"2024 Medical Personnel Training Promotion Project","award":["XJZT24JC15"],"award-info":[{"award-number":["XJZT24JC15"]}]},{"name":"2024 Medical Personnel Training Promotion Project","award":["XJZT24LZ03"],"award-info":[{"award-number":["XJZT24LZ03"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s12149-025-02033-8","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T03:57:04Z","timestamp":1741665424000},"page":"552-566","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Superiority of 68Ga-PSMA-11 PET\/CT over mpMRI for lateralization accuracy of diagnosing intra-glandular prostate cancer lesions: avoiding fluke targeting"],"prefix":"10.1007","volume":"39","author":[{"given":"Min","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyong","family":"Quan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keke","family":"Xin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guiyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taoqi","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weijun","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0267-7819","authenticated-orcid":false,"given":"Fei","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,11]]},"reference":[{"key":"2033_CR1","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1111\/j.1464-410X.2008.07897.x","volume":"102","author":"SK Hong","year":"2008","unstructured":"Hong SK, Han BK, Chung JS, Park DS, Jeong SJ, Byun SS, et al. Evaluation of pT2 subdivisions in the TNM staging system for prostate cancer. Bju int. 2008;102:1092\u20136.","journal-title":"Bju int"},{"key":"2033_CR2","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.eururo.2016.05.043","volume":"70","author":"MC Wong","year":"2016","unstructured":"Wong MC, Goggins WB, Wang HH, Fung FD, Leung C, Wong SY, et al. Global incidence and mortality for prostate cancer: analysis of temporal patterns and trends in 36 countries. Eur Urol. 2016;70:862\u201374.","journal-title":"Eur Urol"},{"key":"2033_CR3","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/S1470-2045(20)30730-0","volume":"22","author":"LA Gharzai","year":"2021","unstructured":"Gharzai LA, Jiang R, Wallington D, Jones G, Birer S, Jairath N, et al. Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis. Lancet oncol. 2021;22:402\u201310.","journal-title":"Lancet oncol"},{"key":"2033_CR4","first-page":"2313","volume":"70","author":"A Villers","year":"1992","unstructured":"Villers A, McNeal JE, Freiha FS, Stamey TA. Multiple cancers in the prostate. Morphologic features of clinically recognized versus incidental tumors. Cancer-Am Cancer Soc. 1992;70:2313\u20138.","journal-title":"Cancer-Am Cancer Soc."},{"key":"2033_CR5","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1007\/s00120-023-02062-z","volume":"62","author":"AE Handke","year":"2023","unstructured":"Handke AE, Albers P, Schimm\u00f6ller L, Bonekamp D, Asbach P, Schlemmer HP, et al. Systematische oder gezielte Fusionsbiopsie der Prostata. Die Urologie. 2023;62:464\u201372.","journal-title":"Die Urologie"},{"key":"2033_CR6","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1007\/s00256-019-03230-z","volume":"48","author":"J Zhou","year":"2019","unstructured":"Zhou J, Gou Z, Wu R, Yuan Y, Yu G, Zhao Y. Comparison of PSMA-PET\/CT, choline-PET\/CT, NaF-PET\/CT, MRI, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a systematic review and meta-analysis. Skeletal Radiol. 2019;48:1915\u201324.","journal-title":"Skeletal Radiol"},{"key":"2033_CR7","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/bju.14858","volume":"126","author":"AA Kalapara","year":"2020","unstructured":"Kalapara AA, Nzenza T, Pan HYC, Ballok Z, Ramdave S, O\u2019Sullivan R, et al. Detection and localisation of primary prostate cancer using (68) gallium prostate-specific membrane antigen positron emission tomography\/computed tomography compared with multiparametric magnetic resonance imaging and radical prostatectomy specimen pathology. BJU Int. 2020;126:83\u201390.","journal-title":"BJU Int"},{"key":"2033_CR8","first-page":"395","volume":"11","author":"L Saule","year":"2021","unstructured":"Saule L, Radzina M, Liepa M, Roznere L, Kalnina M, Lioznovs A, et al. Diagnostic scope of (18)F-PSMA-1007 PET\/CT: comparison with multiparametric MRI and bone scintigraphy for the assessment of early prostate cancer recurrence. Am J Nucl Med Mol Imaging. 2021;11:395\u2013405.","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"2033_CR9","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s00345-014-1362-x","volume":"33","author":"E Rud","year":"2015","unstructured":"Rud E, Klotz D, Rennesund K, Baco E, Johansen TE, Diep LM, et al. Preoperative magnetic resonance imaging for detecting uni- and bilateral extraprostatic disease in patients with prostate cancer. World J Urol. 2015;33:1015\u201321.","journal-title":"World J Urol"},{"key":"2033_CR10","doi-asserted-by":"crossref","unstructured":"Zhang Q, Zang S, Zhang C, Fu Y, Lv X, Zhang Q, et al. Comparison of 68Ga-PSMA-11 PET-CT with mpMRI for preoperative lymph node staging in patients with intermediate to high-risk prostate cancer. J Transl Med. 2017;15.","DOI":"10.1186\/s12967-017-1333-2"},{"key":"2033_CR11","doi-asserted-by":"publisher","first-page":"10963","DOI":"10.1038\/s41598-020-67385-9","volume":"10","author":"Y Li","year":"2020","unstructured":"Li Y, Han D, Wu P, Ren J, Ma S, Zhang J, et al. Comparison of (68)Ga-PSMA-617 PET\/CT with mpMRI for the detection of PCa in patients with a PSA level of 4\u201320 ng\/ml before the initial biopsy. Sci Rep. 2020;10:10963.","journal-title":"Sci Rep"},{"key":"2033_CR12","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1007\/s00259-017-3670-z","volume":"44","author":"WP Fendler","year":"2017","unstructured":"Fendler WP, Eiber M, Beheshti M, Bomanji J, Ceci F, Cho S, et al. (68)Ga-PSMA PET\/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2017;44:1014\u201324.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2033_CR13","doi-asserted-by":"crossref","unstructured":"Mihatsch PW, Beissert M, Pomper MG, Bley TA, Seitz AK, K\u00fcbler H, et al. Changing threshold-based segmentation has no relevant impact on semi-quantification in the context of structured reporting for PSMA-PET\/CT. 2022;14:270.","DOI":"10.3390\/cancers14020270"},{"key":"2033_CR14","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/JU.0000000000002248","volume":"207","author":"M Kachanov","year":"2022","unstructured":"Kachanov M, Leyh-Bannurah SR, Roberts MJ, Sauer M, Beyersdorff D, Boiko S, et al. Optimizing combined magnetic resonance imaging (MRI)-targeted and systematic biopsy strategies: sparing the multiparametric MRI-negative transitional zone in presence of exclusively peripheral multiparametric MRI-suspect lesions. J Urol. 2022;207:333\u201340.","journal-title":"J Urol"},{"key":"2033_CR15","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.juro.2018.06.026","volume":"200","author":"SR Leyh-Bannurah","year":"2018","unstructured":"Leyh-Bannurah SR, Kachanov M, Beyersdorff D, Preisser F, Tilki D, Fisch M, et al. Anterior localization of prostate cancer suspicious lesions in 1,161 patients undergoing magnetic resonance imaging\/ultrasound fusion guided targeted biopsies. J Urol. 2018;200:1035\u201340.","journal-title":"J Urol"},{"issue":"Suppl 1","key":"2033_CR16","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/bju.14794","volume":"124","author":"MJ Scheltema","year":"2019","unstructured":"Scheltema MJ, Chang JI, Stricker PD, van Leeuwen PJ, Nguyen QA, Ho B, et al. Diagnostic accuracy of (68) Ga-prostate-specific membrane antigen (PSMA) positron-emission tomography (PET) and multiparametric (mp)MRI to detect intermediate-grade intra-prostatic prostate cancer using whole-mount pathology: impact of the addition of (68) Ga-PSMA PET to mpMRI. BJU Int. 2019;124(Suppl 1):42\u20139.","journal-title":"BJU Int"},{"key":"2033_CR17","doi-asserted-by":"publisher","first-page":"847","DOI":"10.2967\/jnumed.121.262398","volume":"63","author":"I Sonni","year":"2022","unstructured":"Sonni I, Felker ER, Lenis AT, Sisk AE, Bahri S, Allen-Auerbach M, et al. Head-to-head comparison of (68)Ga-PSMA-11 PET\/CT and mpMRI with a histopathology gold standard in the detection, intraprostatic localization, and determination of local extension of primary prostate cancer: results from a prospective single-center imaging trial. J Nucl Med. 2022;63:847\u201354.","journal-title":"J Nucl Med"},{"key":"2033_CR18","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1002\/cncr.22858","volume":"110","author":"V Mouraviev","year":"2007","unstructured":"Mouraviev V, Mayes JM, Sun L, Madden JF, Moul JW, Polascik TJ. Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer. Cancer. 2007;110:906\u201310.","journal-title":"Cancer"},{"key":"2033_CR19","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.urolonc.2021.04.021","volume":"39","author":"Z Zhou","year":"2021","unstructured":"Zhou Z, Zhou Y, Yan W, Sun H, Li Q, Li H, et al. Unilateral lesion detected on preoperative multiparametric magnetic resonance imaging and MRI\/US fusion-guided prostate biopsy is not an appropriate indication for focal therapy in prostate cancer. Urol Oncol. 2021;39:730.","journal-title":"Urol Oncol"},{"key":"2033_CR20","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1097\/JU.0000000000000757","volume":"204","author":"MA Pagniez","year":"2020","unstructured":"Pagniez MA, Kasivisvanathan V, Puech P, Drumez E, Villers A, Olivier J. Predictive factors of missed clinically significant prostate cancers in men with negative magnetic resonance imaging: a systematic review and meta-analysis. J Urol. 2020;204:24\u201332.","journal-title":"J Urol"},{"key":"2033_CR21","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1007\/s00330-018-5664-z","volume":"29","author":"S Krishna","year":"2019","unstructured":"Krishna S, Schieda N, McInnes MD, Flood TA, Thornhill RE. Diagnosis of transition zone prostate cancer using T2-weighted (T2W) MRI: comparison of subjective features and quantitative shape analysis. Eur Radiol. 2019;29:1133\u201343.","journal-title":"Eur Radiol"},{"key":"2033_CR22","unstructured":"Carroll PPCA, Greene K, Babaian RJ, Carter HB, Gann PH, Han M, et al. PSA testing for the pretreatment staging and posttreatment management of prostate cancer: 2013 Revision of 2009 Best Practice Statement. American Urological Association; 2013."},{"key":"2033_CR23","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1111\/andr.13041","volume":"9","author":"M Pecoraro","year":"2021","unstructured":"Pecoraro M, Messina E, Bicchetti M, Carnicelli G, Del Monte M, Iorio B, et al. The future direction of imaging in prostate cancer: MRI with or without contrast injection. Andrology. 2021;9:1429\u201343.","journal-title":"Andrology"},{"key":"2033_CR24","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.juro.2016.07.084","volume":"197","author":"A Priester","year":"2017","unstructured":"Priester A, Natarajan S, Khoshnoodi P, Margolis DJ, Raman SS, Reiter RE, et al. Magnetic resonance imaging underestimation of prostate cancer geometry: use of patient specific molds to correlate images with whole mount pathology. J Urol. 2017;197:320\u20136.","journal-title":"J Urol"},{"issue":"3","key":"2033_CR25","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2967\/jnumed.117.198119","volume":"59","author":"M Eiber","year":"2017","unstructured":"Eiber M, Herrmann K, Calais J, Hadaschik B, Giesel FL, Hartenbach M, et al. Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET\/CT. J NUCL MED. 2017;59(3):469\u201378.","journal-title":"J NUCL MED"},{"issue":"1","key":"2033_CR26","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s00259-024-06857-w","volume":"52","author":"SA Esfahani","year":"2024","unstructured":"Esfahani SA, Morris MJ, Sartor O, Frydenberg M, Fanti S, Calais J, et al. Standardized template for clinical reporting of PSMA PET\/CT scans. Eur J Nucl Med Mol I. 2024;52(1):335\u201341.","journal-title":"Eur J Nucl Med Mol I"},{"issue":"9","key":"2033_CR27","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/S1470-2045(24)00339-5","volume":"25","author":"K Bouchelouche","year":"2024","unstructured":"Bouchelouche K, Choyke PL. Use of PROMISE criteria on PSMA-PET for prediction of overall survival in prostate cancer. Lancet Oncol. 2024;25(9):1107\u20138.","journal-title":"Lancet Oncol"},{"issue":"4","key":"2033_CR28","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2967\/jnumed.119.232504","volume":"61","author":"A Toriihara","year":"2019","unstructured":"Toriihara A, Nobashi T, Baratto L, Duan H, Moradi F, Park S, et al. Comparison of 3 interpretation criteria for 68Ga-PSMA11 PET based on inter- and intrareader agreement. J Nucl Med. 2019;61(4):533\u20139.","journal-title":"J Nucl Med"},{"issue":"3","key":"2033_CR29","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/bju.15152","volume":"126","author":"MY Chen","year":"2020","unstructured":"Chen MY, Franklin A, Yaxley J, Gianduzzo T, McBean R, Wong D, et al. Solitary rib lesions showing prostate-specific membrane antigen (PSMA) uptake in pre-treatment staging 68Ga-PSMA-11 positron emission tomography scans for men with prostate cancer: benign or malignant? BJU Int. 2020;126(3):396\u2013401.","journal-title":"BJU Int"},{"issue":"4","key":"2033_CR30","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1055\/s-0044-1787733","volume":"23","author":"\u00d6 Vural Topuz","year":"2024","unstructured":"Vural Topuz \u00d6, Aksu A. BaselineGa-68 PSMA PET-derived primary tumor parameters in patients with prostate cancer and their association with clinical risk stratification and clinicopathologic features. World J Nucl Med. 2024;23(4):227\u201333.","journal-title":"World J Nucl Med"},{"issue":"3","key":"2033_CR31","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s00259-024-06949-7","volume":"52","author":"Y Li","year":"2025","unstructured":"Li Y, Li J, Yang J, Xiao L, Zhou M, Cai Y, et al. Using a novel PSMA-PET and PSA-based model to enhance the diagnostic accuracy for clinically significant prostate cancer and avoid unnecessary biopsy in men with PI-RADS \u2264 3 MRI. Eur J Nucl Med Mol I. 2025;52(3):913\u201324.","journal-title":"Eur J Nucl Med Mol I"},{"issue":"1","key":"2033_CR32","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/RLU.0000000000004951","volume":"49","author":"S Guo","year":"2023","unstructured":"Guo S, Kang F, Ma S, Jiao J, Ren J, Wang J, et al. The PRIMARY score: diagnostic performance and added value compared with MRI in detecting clinically significant prostate cancer. Clin Nucl Med. 2023;49(1):37\u201344.","journal-title":"Clin Nucl Med"},{"key":"2033_CR33","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","volume":"5","author":"WP Fendler","year":"2019","unstructured":"Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, et al. Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial. JAMA Oncol. 2019;5:856\u201363.","journal-title":"JAMA Oncol"},{"key":"2033_CR34","doi-asserted-by":"publisher","first-page":"668","DOI":"10.2967\/jnumed.115.154153","volume":"56","author":"M Eiber","year":"2015","unstructured":"Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, et al. Evaluation of hybrid 68Ga-PSMA ligand PET\/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56:668\u201374.","journal-title":"J Nucl Med"},{"key":"2033_CR35","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.2967\/jnumed.115.160382","volume":"56","author":"JJ Morigi","year":"2015","unstructured":"Morigi JJ, Stricker PD, van Leeuwen PJ, Tang R, Ho B, Nguyen Q, et al. Prospective comparison of 18F-fluoromethylcholine versus 68Ga-PSMA PET\/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med. 2015;56:1185\u201390.","journal-title":"J Nucl Med"},{"key":"2033_CR36","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.2967\/jnumed.116.184457","volume":"58","author":"I Einspieler","year":"2017","unstructured":"Einspieler I, Rauscher I, D\u00fcwel C, Kr\u00f6nke M, Rischpler C, Habl G, et al. Detection efficacy of hybrid (68)Ga-PSMA ligand PET\/CT in prostate cancer patients with biochemical recurrence after primary radiation therapy defined by phoenix criteria. J Nucl Med. 2017;58:1081\u20137.","journal-title":"J Nucl Med"},{"key":"2033_CR37","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s00259-017-3858-2","volume":"45","author":"B Grubm\u00fcller","year":"2018","unstructured":"Grubm\u00fcller B, Baltzer P, D\u2019Andrea D, Korn S, Haug AR, Hacker M, et al. (68)Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy\u2014diagnostic performance and impact on therapeutic decision-making. Eur J Nucl Med Mol Imaging. 2018;45:235\u201342.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2033_CR38","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1007\/s00259-020-04827-6","volume":"47","author":"S Spohn","year":"2020","unstructured":"Spohn S, Jaegle C, Fassbender TF, Sprave T, Gkika E, Nicolay NH, et al. Intraindividual comparison between (68)Ga-PSMA-PET\/CT and mpMRI for intraprostatic tumor delineation in patients with primary prostate cancer: a retrospective analysis in 101 patients. Eur J Nucl Med Mol Imaging. 2020;47:2796\u2013803.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2033_CR39","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.radonc.2019.07.005","volume":"141","author":"AS Bettermann","year":"2019","unstructured":"Bettermann AS, Zamboglou C, Kiefer S, Jilg CA, Spohn S, Kranz-Rudolph J, et al. [(68)Ga-]PSMA-11 PET\/CT and multiparametric MRI for gross tumor volume delineation in a slice by slice analysis with whole mount histopathology as a reference standard\u2014implications for focal radiotherapy planning in primary prostate cancer. Radiother Oncol. 2019;141:214\u20139.","journal-title":"Radiother Oncol"},{"key":"2033_CR40","doi-asserted-by":"publisher","first-page":"596","DOI":"10.2967\/jnumed.120.257238","volume":"62","author":"A Farolfi","year":"2021","unstructured":"Farolfi A, Calderoni L, Mattana F, Mei R, Telo S, Fanti S, et al. Current and emerging clinical applications of PSMA PET diagnostic imaging for prostate cancer. J Nucl Med. 2021;62:596\u2013604.","journal-title":"J Nucl Med"},{"key":"2033_CR41","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s00345-017-2135-0","volume":"36","author":"F Steinkohl","year":"2018","unstructured":"Steinkohl F, Gruber L, Bektic J, Nagele U, Aigner F, Herrmann TRW, et al. Retrospective analysis of the development of PIRADS 3 lesions over time: when is a follow-up MRI reasonable? World J Urol. 2018;36:367\u201373.","journal-title":"World J Urol"},{"key":"2033_CR42","doi-asserted-by":"publisher","first-page":"70","DOI":"10.21037\/tau.2017.12.31","volume":"7","author":"IG Schoots","year":"2018","unstructured":"Schoots IG. MRI in early prostate cancer detection: how to manage indeterminate or equivocal PI-RADS 3 lesions? Transl Androl Urol. 2018;7:70\u201382.","journal-title":"Transl Androl Urol"},{"key":"2033_CR43","doi-asserted-by":"publisher","first-page":"228","DOI":"10.7150\/thno.16638","volume":"7","author":"C Zamboglou","year":"2017","unstructured":"Zamboglou C, Drendel V, Jilg CA, Rischke HC, Beck TI, Schultze-Seemann W, et al. Comparison of (68)Ga-HBED-CC PSMA-PET\/CT and multiparametric MRI for gross tumour volume detection in patients with primary prostate cancer based on slice by slice comparison with histopathology. Theranostics. 2017;7:228\u201337.","journal-title":"Theranostics"},{"key":"2033_CR44","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1002\/jmri.25711","volume":"46","author":"EC Ehman","year":"2017","unstructured":"Ehman EC, Johnson GB, Villanueva-Meyer JE, Cha S, Leynes A, Larson P, et al. PET\/MRI: where might it replace PET\/CT? J Magn Reson Imaging. 2017;46:1247\u201362.","journal-title":"J Magn Reson Imaging"},{"key":"2033_CR45","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.eururo.2021.08.002","volume":"80","author":"L Emmett","year":"2021","unstructured":"Emmett L, Buteau J, Papa N, Moon D, Thompson J, Roberts MJ, et al. The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY): a prospective multicentre study. Eur Urol. 2021;80:682\u20139.","journal-title":"Eur Urol"},{"key":"2033_CR46","doi-asserted-by":"publisher","first-page":"194","DOI":"10.2967\/jnumed.118.225276","volume":"61","author":"B Kranzb\u00fchler","year":"2020","unstructured":"Kranzb\u00fchler B, M\u00fcller J, Becker AS, Garcia Sch\u00fcler HI, Muehlematter U, Fankhauser CD, et al. Detection rate and localization of prostate cancer recurrence using (68)Ga-PSMA-11 PET\/MRI in patients with low PSA values \u2264 0.5 ng\/mL. J Nucl Med. 2020;61:194\u2013201.","journal-title":"J Nucl Med"},{"key":"2033_CR47","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00259-018-4066-4","volume":"46","author":"A Farolfi","year":"2019","unstructured":"Farolfi A, Ceci F, Castellucci P, Graziani T, Siepe G, Lambertini A, et al. (68)Ga-PSMA-11 PET\/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5\u00a0ng\/ml. Efficacy and impact on treatment strategy. Eur J Nucl Med Mol Imaging. 2019;46:11\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2033_CR48","doi-asserted-by":"publisher","first-page":"944","DOI":"10.2967\/jnumed.118.221010","volume":"60","author":"M Chen","year":"2019","unstructured":"Chen M, Zhang Q, Zhang C, Zhao X, Marra G, Gao J, et al. Combination of (68)Ga-PSMA PET\/CT and multiparametric MRI improves the detection of clinically significant prostate cancer: a lesion-by-lesion analysis. J Nucl Med. 2019;60:944\u20139.","journal-title":"J Nucl Med"},{"key":"2033_CR49","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1002\/cncr.24258","volume":"115","author":"TJ Polascik","year":"2009","unstructured":"Polascik TJ, Mayes JM, Schroeck FR, Sun L, Madden JF, Moul JW, et al. Patient selection for hemiablative focal therapy of prostate cancer: variables predictive of tumor unilaterality based upon radical prostatectomy. Cancer. 2009;115:2104\u201310.","journal-title":"Cancer"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-025-02033-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-025-02033-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-025-02033-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T05:04:40Z","timestamp":1747803880000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-025-02033-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,11]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["2033"],"URL":"https:\/\/doi.org\/10.1007\/s12149-025-02033-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5416986\/v1","asserted-by":"object"}]},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,11]]},"assertion":[{"value":"8 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Medical Ethics Committee of the First Affiliated Hospital of the Air Force Medical University (approval no. KY20162088-1). All procedures performed in this study were performed in accordance with the 1964 Helsinki Declaration and its later amendments or comparable ethics standards. Informed consent to participate was obtained from all patients included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication was obtained from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}